Wednesday, July 26, 2017

Enter Title

Minimize
Current Australian Clinical Trials


The Ambition Trial:

The purpose of this study is to compare two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line mono therapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to clinical failure events.

Click here to download more information.

The GRIPHON Trial:

A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary hypertension.

Participating sites:

- John Hunter Hospital: Judy Knapp 02 49214095
- Royal Adelaide Hospital: P.King 08 82222910 / 0401 598 675
- Royal Hobart Hospital: Prof David Kilpatrick 03 62143085
- Royal Melbourne Hospital: Susanne Schulz 03 93428490
- Royal Perth Hospital: Louise Moran 08 9224 2747
- St Vincents Hospital Melbourne: Dr Wendy Stevens 03 92882211
- St Vincents Hospital Sydney: Dr Eugene Kotlyar 02 83823785
- The Prince Charles Hospital QLD: Paul Ve 0731395159
Copyright 2011 by PHSANZ